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Abstract
Objective: To examine the efficacy of a new topical capsaicin presentation as an oral rinse in improving the symp-
toms of burning mouth syndrome (BMS).
Study design: A prospective, double-blind, cross-over study was made of 30 patients with BMS. There were 7 
dropouts; the final study series thus comprised 23 individuals. The patients were randomized to two groups: (A) 
capsaicin rinse (0.02%) or (B) placebo rinse, administered during one week. After a one-week washout period, 
the patients were then assigned to the opposite group. Burning discomfort was scored using a visual analog scale 
(VAS): in the morning before starting the treatment, in the afternoon on the first day of treatment, and at the end 
of the week of treatment in the morning and in the afternoon. The same scoring sequence was again applied one 
week later with the opposite rinse.
Results: The mean patient age was 72.65 ± 12.10 years, and the duration of BMS was 5.43 ± 3.23 years on average. 
Significant differences in VAS score were recorded in the capsaicin group between baseline in the morning (AM1) 
or afternoon (AA1) and the end of the week of treatment (AA7)(p=0.003 and p=0.002, respectively).
Conclusion: The topical application of capsaicin may be useful in treating the discomfort of BMS, but has 
some limitations.
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Introduction
Burning mouth syndrome (BMS) manifests as a burning 
sensation of the tongue, lips or entire oral cavity, in the 
absence of any objective lesions or laboratory test find-
ings capable of accounting for the discomfort (1). Patients 
with BMS usually have other associated conditions such 
as dry mouth or taste alterations – these manifestations 
being common in situations of anxiety or depression (2). 
Most affected subjects are females, particularly postmen-
opausal women. The revised chronic pain classification 
of the International Headache Socie-ty (Headache Clas-
sification 2004) defines BMS as a burning sensation for 
which no medical or dental cause can be established (3).
The diagnosis of the syndrome is based on the clini-
cal manifestations. The underlying cause is unknown, 
though many potentially influencing conditions have 
been cited, such as local, general and psychopathologi-
cal factors. More recently, BMS has been associated to a 
neuropathic mechanism affecting peripheral or central 
levels of the nervous system (4-6).
Very few cases of spontaneous remission of the symp-
toms have been reported. The treatments proposed 
for controlling the discomfort caused by BMS include 
alpha-lipoic acid, cognitive-behavioral therapy, the 
administration of anticonvulsivants (particularly clon-
azepam), and topical capsaicin (3,7,8). However, most 
of the studies lack controls, the measurements are not 
reproducible, and the sample sizes are limited (3). 
Topical capsaicin has been used as a treatment alternative 
for controlling neuropathic pain. This substances induc-
es desensitization to thermal, chemical and mechanical 
stimuli. It has also been used for the treatment of the dis-
comfort caused by BMS, with positive results. Petruzzi et 
al. (9) showed 0.025% capsaicin via the systemic route to 
be effective in the context of short treatments. The drug 
has also been used topically, with good results (10).
The present study was designed to examine the efficacy 
of a new topical capsaicin presentation as an oral rinse in 
improving the symptoms of BMS. In addition, the pos-
sible adverse effects of such treatment were evaluated.
Materials and Methods
-Study design
A prospective, double-blind, cross-over study was made 
involving randomized patient distribution to treatment. 
BMS was diagnosed according to the current criteria, 
and the discomfort had been present on a daily basis 
for at least 6 months (2). A visual analog scale (VAS) 
was used to score discomfort at different times during 
the study (0 cm = no discomfort, 10 cm = unbearable or 
maximum discomfort).
The patients were randomized to two groups: (A) 0.02% 
capsaicin rinse or (B) placebo, administered three times 
a day. The rinses were applied for about 30 seconds in 
volumes of 15 ml. A baseline assessment of discomfort 
was made in the morning before treatment in both the 
capsaicin group (AM1) and in the placebo group (BM1). 
The VAS score was then again recorded in the after-
noon of the first day of treatment in both groups (AA1 
and BA1) and at the end of one week of treatment in 
both groups, in the morning (AM7 and BM7) and in the 
afternoon (AA7 and BA7). After this first week of treat-
ment, the patients completed a one-week washout pe-
riod (no rinses, only regular dental hygiene in the form 
of tooth brushing), after which they were assigned to 
the opposite group for a further week of treatment. 
During this cross-over period, treatment and the scor-
ing of discomfort were carried out in the same way as 
in the first week, but administering the opposite oral 
rinse. Thus, all of the patients used both rinses (capsai-
cin and placebo) and were scored for discomfort at the 
start of the study, after one week, and again after three 
weeks. The patients were also questioned about possible 
adverse effects or discomfort caused by the treatments. 
-Patient selection
Since this was a pilot study and the number of publica-
tions on topical capsaicin for treating BMS is limited, 
we analyzed 23 patients (19 females and 4 males) out 
of a total of 30 initially planned subjects (7 dropped out 
in the first week of the study). The patients were rand-
omized at the start of the first week (12 in one group and 
11 in the other).
The study included patients diagnosed with BMS and 
with a minimum duration of the disease of 6 months. 
The enrolled subjects were required to use no speci-
fic medication or treatment capable of interfering with 
BMS, for at least one month prior to the start of the study, 
and written informed was obtained in all cases. On the 
other hand, patients with contraindications to topical 
capsaicin treatment were excluded from the study, as 
were those with serious systemic disease at the time of 
patient screening, patients with oral mucosal lesions 
that might explain the burning sensation, and subjects 
unable to correctly score discomfort on the VAS scale. 
Lastly, where indicated, those subjects who developed 
adverse effects were removed from the study.
The study was approved by the Clinical Research Ethics 
Committee of Dr. Peset University Hospital (Valencia, 
Spain).
-Data analysis
The SPSS version 15.0 statistical package for Microsoft 
Windows was used to analyze the data. Qualitative va-
riables were represented by their absolute (n) and rela-
tive (%) frequencies, while quantitative variables were 
reported as the median and range. The effects of the 
capsaicin rinse and placebo formulation were evaluated, 
comparing the distribution of the VAS scores for each 
rinse at the different study timepoints (AM1, AA1, BM1, 
BA1, AM7, AA7, BM7, BA7), based on the Wilcoxon test. 
Statistical significance was considered for p < 0.05.
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Results
The study initially involved 30 patients, of which 7 
(23.3%) abandoned the trial in the first week of treat-
ment. Of these 7 individuals, four belonged to the cap-
saicin group (2 claimed to have noted no therapeutic ef-
fect, while the other two complained of greatly increased 
burning sensation when using the rinse). In turn, in the 
control group three patients abandoned the study during 
the first week because of a lack of therapeutic effect.
Thus, the study finally comprised 23 patients with BMS 
yielding cross-over measurements of discomfort (23 in 
group A and 23 in group B).
The mean patient age was 72.65 ± 12.10 years (range 
40-90 years). Most of the patients (65.2%) were between 
70 and 80 years of age. The mean duration of the disease 
was 5.43 ± 3.23 years (range 1-14 years). Patients with 
a BMS duration of 4 and 5 years represented 39.1% of 
the total (n = 9).
On examining the VAS scores at the start and end of 
the first week in both groups (A and B), based on the 
Wilcoxon test, differences were found between 0.02% 
capsaicin in the morning (AM1) and afternoon of the 
first day (AA1) and end of the week (AA7)(Z = -2.31, 
p=0.003 for AM1 and Z = -2.96, p=0.002 for AA1)(Fig. 
1). No such differences were found in the case of the 
placebo rinse (control group B).
Regarding side effects, intense burning sensation was 
described by one-third of the subjects during and for a 
few minutes (maximum 20 minutes) after application of 
the capsaicin rinse. 
Fig. 1. Comparison of the mean 
visual analog scale (VAS) scores 
between timepoints during the first 
week of treatment with the capsai-
cin rinse (group A): AM1: Baseline 
score in the morning of the first day 
of the first week of treatment. AA1: 
Score in the afternoon of the first 
day of the week of capsaicin treat-
ment. AM7: Score in the morning of 
the last day of the week of capsaicin 
treatment. AA7: Score in the after-
noon of the last day of the week of 
capsaicin treatment.
Discussion
Burning sensation affecting the tongue, lips or entire 
oral cavity may be a symptom of some underlying dis-
order affecting the oral mucosa, or may be the princi-
pal manifestation of a form of idiopathic stomatodynia 
known as burning mouth syndrome (BMS) (11). The lat-
ter is a chronic condition affecting mainly elderly wo-
men (as in our own series). In this context, older patients 
with BMS are known to be more refractory to treatment 
of the syndrome. A great variety of drugs have been 
used, though to date no effective management strategy 
has been established (8).
In our study capsaicin was evaluated in oral rinse for-
mulation, which showed a degree of efficacy in improv-
ing the symptoms of BMS over short periods of time. In 
effect, the visual analog scale (VAS) used to score dis-
comfort revealed significant improvement of at least two 
points on average after 7 days of treatment with capsai-
cin rinse versus baseline. No such improvement was ob-
served with the placebo formulation. The patients were 
recruited on the basis of strict and homogeneous diagnos-
tic criteria. In this sense, many of the studies published to 
date lack such strict criteria, and the sample characteris-
tics moreover vary from one study to another (3).
Petruzzi et al. (9) also observed evident improvement, but 
in their case capsaicin was administered via the systemic 
route during four weeks. As adverse effects, these authors 
recorded problems such as gastric pain, which limited ad-
ministration of the drug via this route. Their improvement 
rate (32%, n = 8) was very similar to our own.
However, it should be noted that there are clear limita-
tions to the use of topical capsaicin, such as limited effect 
over time and a limited magnitude of improvement (12). 
While the patients showed improvement from the start 
to the end of the week of treatment with the active drug 
formulation, it is also true that the magnitude of such im-
provement was limited (only 2 points on the VAS on a-
verage) – with no complete remission of symptoms in any 
patient, and no lasting improvement over time.
Moreover, the burning sensation produced on using the 
capsaicin rinse limits its use – though the discomfort 
threshold varies among patients (13,14).
Topical capsaicin has been used as a treatment alternative 
for controlling neuropathic pain in general. The drug is 
normally used at concentrations of between 0.025% and 
0.075%, inducing desensitization to thermal, chemical 
and mechanical stimuli when applied topically (15).
The mechanism of action involves interaction of capsai-
cin with the vanilloid receptor (VR1) of the C type sen-
sory nerve fibers (16). These receptors are non-selective 
cation channels showing high calcium permeability. In 
this context, capsaicin inhibits the biosynthesis and ax-
onal transport of substance P, a mediator of nociceptive 
impulses from peripheral stimulation sites towards the 
central nervous system. Most capsaicin-sensitive fib-
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ers terminate in polymodal nociceptors that respond to 
a broad range of stimuli (heat, pressure and irritants). 
Topical capsaicin induces selective and reversible desen-
sitization of the afferent sensory C fiber endings. Tak-
ing into account that the amyelinic C fibers in the oral 
mucosa have been implicated in burning sensation in 
BMS, in the context of the neuropathic hypothesis of the 
disease (17,18), topical capsaicin should be considered in 
the management of BMS, though taking into account its 
limited effect over time and the discomfort caused during 
use of the oral rinse in one-third of all patients.
References 
1. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am 
Fam Physician.2002;65:615-20. 
2. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino 
MA. Update onburning mouth syndrome: overview and patient ma-
nagement. Crit Rev Oral Biol Med.2003;14:275-91. 
3. Zakrzewska JM, Forssell H, Glenny AM. Interventions for the 
treatment ofburning mouth syndrome. Cochrane Database Syst Rev. 
2005;1:CD002779.
4. Jääskeläinen SK, Forssell H, Tenovuo O. Abnormalities of the 
blink reflex inburning mouth syndrome. Pain. 1997;73:455-60. 
5. Jääskeläinen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, 
Sonninen P, et al. Role of the dopaminergic system in chronic pain 
-- a fluorodopa-PETstudy. Pain. 2001;90:257-60. 
6. Grémeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, 
Woda A. Effect oflingual nerve block on burning mouth syndrome 
(stomatodynia): a randomizedcrossover trial. Pain. 2010;149:27-32. 
7. Epstein JB, Marcoe JH. Topical application of capsaicin for 
treatment of oral neuropathic pain and trigeminal neuralgia. Oral 
Surg Oral Med Oral Pathol.1994;77:135-40. 
8. Lynn B. Capsaicin: actions on nociceptive C-fibres and therapeutic 
potential. Pain. 1990;41:61-9. 
9. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R. 
Systemiccapsaicin for burning mouth syndrome: short-term results 
of a pilot study. J OralPathol Med. 2004;33:111-4. 
10. Simons CT, O’Mahony M, Carstens E. Taste suppression fo-
llowing lingualcapsaicin pre-treatment in humans. Chem Senses. 
2002;27:353-65. 
11. Rojo L, Silvestre FJ, Bagan JV, De Vicente T. Psychiatric mor-
bidity in burningmouth syndrome. Psychiatric interview versus 
depression and anxiety scales. Oral Surg Oral Med Oral Pathol. 
1993;75:308-11. 
12. Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carras-
si A. Burning mouthsyndrome: a retrospective study investiga-
ting spontaneous remission and response to treatments. Oral Dis. 
2006;12:152-5. 
13. Spice R, Hagen NA. Capsaicin in burning mouth syndrome: titra-
tion strategies. J Otolaryngol. 2004;33:53-4. 
14. Just T, Steiner S, Pau HW. Oral pain perception and taste in bur-
ning mouthsyndrome. J Oral Pathol Med. 2010;39:22-7. 
15. Elitt CM, Malin SA, Koerber HR, Davis BM, Albers KM. Ove-
rexpression of arteminin the tongue increases expression of TRPV1 
and TRPA1 in trigeminal afferents andcauses oral sensitivity to cap-
saicin and mustard oil. Brain Res. 2008;1230:80-90. 
16. Yilmaz Z, Renton T, Yiangou Y, Zakrzewska J, Chessell IP, 
Bountra C, et al.Burning mouth syndrome as a trigeminal small fibre 
neuropathy: Increased heat andcapsaicin receptor TRPV1 in nerve 
fibres correlates with pain score. J ClinNeurosci. 2007;14:864-71. 
17. López-Jornet P, Camacho-Alonso F, Andujar-Mateos P, Sánchez-
Siles M,Gómez-Garcia F. Burning mouth syndrome: an update. Med 
Oral Patol Oral Cir Bucal.2010;15:e562-8. 
18. Mínguez Serra MP, Salort Llorca C, Silvestre Donat FJ. Pharma-
cologicaltreatment of burning mouth syndrome: A review and upda-
te. Med Oral Patol Oral CirBucal. 2007;12:E299-304.
 References with links to Crossref - DOI    
